Esperion to cut work force 40%
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), developers of a new class of cholesterol-lowering drugs, announced a 40 percent work force reduction and said it would focus its marketing efforts more …
Esperion loss grows as sales effort ramps up
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a loss of $90.8 million or $3.50 a share in the first quarter ended March 31, vs. a loss of $78.2 million or …
Esperion expands licensing deal with Daiichi Sankyo Group
Esperion expands partnership with Daiichi Sankyo Group ANN ARBOR–Esperion Therapeutics (NASDAQ: ESPR), developers of a new class of cholesterol-lowering drugs, announced it has entered into a licensing agreement with Daiichi …
Nexletol combo cuts bad cholesterol 60.5 percent in new study
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based developer of cholesterol-lowering drugs, announced that the results of a Phase 2 study evaluating the combination of its Nexletol (bempedoic acid) …
Esperion posts big loss, but sales of its drugs rising rapidly
ANN ARBOR—Esperion Therapeutics Inc. reported a 150 percent increase in sales for its new cholesterol-lowering drug between the third quarter and the fourth quarter ended Dec. 31. Overall, the company …
Esperion drug candidate named top innovation of 2020
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-fighting drugs, announced that its lead drug candidate, bempedoic acid, was included in the …
Esperion in $200M capital deal with New York private equity firm
ANN ARBOR—Officials at Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR), a pharmaceutical startup developing a new class of cholesterol-lowering drugs, announced a $200 million funding agreement with an investor group …